aleglitazar

A dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Aleglitazar binds to both PPARalpha and PPARgamma and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
024620092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
IMPORTANCE No therapy directed against diabetes has been shown to unequivocally reduce the excess risk of cardiovascular… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
BACKGROUND AND PURPOSE Aleglitazar is a dual PPARα/γ agonist but little is known about its effects on vascular function and… (More)
Is this relevant?
2013
2013
BACKGROUND Peroxisome proliferator-activated receptors (PPARs) regulate transcription of genes involved in glucose uptake, lipid… (More)
Is this relevant?
2012
2012
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors that control the expression of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2011
2011
BACKGROUND Aleglitazar is a new, balanced dual peroxisome proliferator-activated receptor (PPAR)α/γ agonist designed to optimize… (More)
Is this relevant?
2011
2011
BACKGROUND Glycemic control and management of dyslipidemia to reduce cardiovascular risk are major therapeutic goals in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
This multicenter, randomized, double-blind, placebo-controlled, ascending-dose study investigated the pharmacokinetics… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Preventing morbidity and mortality from diabetes mellitus is of paramount importance as the incidence of this disease is… (More)
Is this relevant?
Highly Cited
2009
2009
2009
Design, synthesis, and SAR of novel alpha-alkoxy-beta-arylpropionic acids as potent and balanced PPARalphagamma coagonists are… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?